SEC Filing Summary: Biozone Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Biozone Pharmaceuticals, Inc. (Note: Request metadata referenced "Cocrystal Pharma, Inc.", but the filing text identifies the registrant as Biozone Pharmaceuticals, Inc.) on October 31, 2013, covering events occurring on October 25, 2013. The filing details a private placement financing round and related corporate governance amendments.
Key Financial Metrics and Transaction Details
- Capital Raised: Gross proceeds of $3,500,000 from the sale of 3,500 shares of Series A Preferred Stock to 22 accredited investors.
- Net Proceeds: $3,410,000.
- Instrument Terms:
- Series A Preferred Stock: Stated value of $1,000 per share.
- Conversion: Convertible into 7,000,000 shares of common stock at a price of $0.50 per share.
- Dividends: 10% per annum, payable quarterly starting June 30, 2014. The Company may elect to pay dividends in common stock subject to specific equity conditions.
- Warrants: Investors received 7,000,000 10-year warrants exercisable at $0.50 per share.
- Liquidity and Debt: The filing does not provide data on existing debt, operating cash flow, or general liquidity positions outside of the new capital raised.
Material Changes
The primary material change is the increase in equity capital and the authorization of a new class of preferred stock. The Company filed a Certificate of Designation to its Articles of Incorporation to authorize the 3,500 shares of Series A Preferred Stock. This transaction introduces a new capital structure with liquidation preferences and voting rights on an as-converted basis for the Series A holders.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were sold under Section 4(a)(2) and Rule 506(b) exemptions. A contingency exists regarding dividend payments: the Company's right to pay dividends in common stock rather than cash is subject to meeting certain equity conditions.
Investor Verification Checklist
- Verify the exact identity of the registrant (Biozone Pharmaceuticals, Inc.) versus the metadata request (Cocrystal Pharma, Inc.).
- Confirm the specific "equity conditions" required to pay dividends in stock rather than cash as detailed in the Securities Purchase Agreement (Exhibit 10.1).
- Review the Certificate of Designation (Exhibit 3.1) for any additional restrictions on the Series A Preferred Stock.
- Assess the dilution impact of the 7,000,000 shares from conversion and the 7,000,000 warrant shares on existing common shareholders.